Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Cardax

OTCPK:CDXI
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CDXI
OTCPK
$5M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
CDXI Share Price and Events
7 Day Returns
0%
OTCPK:CDXI
6.2%
US Pharmaceuticals
8%
US Market
1 Year Returns
-83.3%
OTCPK:CDXI
0.7%
US Pharmaceuticals
-8.1%
US Market
CDXI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cardax (CDXI) 0% 0% -45.5% -83.3% -85.4% -90.6%
US Pharmaceuticals 6.2% -0.1% -7% 0.7% 12.3% 7.3%
US Market 8% -4.5% -17.8% -8.1% 13.2% 23.7%
1 Year Return vs Industry and Market
  • CDXI underperformed the Pharmaceuticals industry which returned 0.7% over the past year.
  • CDXI underperformed the Market in United States of America which returned -8.1% over the past year.
Price Volatility
CDXI
Industry
5yr Volatility vs Market

CDXI Value

 Is Cardax undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Cardax is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cardax has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cardax. This is due to cash flow or dividend data being unavailable. The share price is $6.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cardax's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cardax's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CDXI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-7.49
OTCPK:CDXI Share Price ** OTCPK (2020-03-27) in USD $6
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.76x
United States of America Market PE Ratio Median Figure of 2,949 Publicly-Listed Companies 13.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cardax.

OTCPK:CDXI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:CDXI Share Price ÷ EPS (both in USD)

= 6 ÷ -7.49

-0.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cardax is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Cardax is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cardax's expected growth come at a high price?
Raw Data
OTCPK:CDXI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.93x
United States of America Market PEG Ratio Median Figure of 2,009 Publicly-Listed Companies 0.9x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cardax, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cardax's assets?
Raw Data
OTCPK:CDXI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-10.47
OTCPK:CDXI Share Price * OTCPK (2020-03-27) in USD $6
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.46x
United States of America Market PB Ratio Median Figure of 5,163 Publicly-Listed Companies 1.29x
OTCPK:CDXI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:CDXI Share Price ÷ Book Value per Share (both in USD)

= 6 ÷ -10.47

-0.57x

* Primary Listing of Cardax.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cardax has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.

Next steps:

  1. Take a look at our analysis of CDXI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Pharmaceuticals industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Cardax's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cardax has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CDXI Future Performance

 How is Cardax expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cardax has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cardax expected to grow at an attractive rate?
  • Unable to compare Cardax's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cardax's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Cardax's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:CDXI Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 6.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CDXI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CDXI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -4 -5
2019-09-30 1 -4 -5
2019-06-30 1 -3 -4
2019-03-31 1 -3 -4
2018-12-31 2 -3 -4
2018-09-30 1 -3 -4
2018-06-30 1 -3 -3
2018-03-31 1 -3 -3
2017-12-31 1 -2 -2
2017-09-30 1 -2 -2
2017-06-30 0 -1 -2
2017-03-31 0 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cardax is high growth as no earnings estimate data is available.
  • Unable to determine if Cardax is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CDXI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cardax Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CDXI Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -7.49
2019-09-30 -6.81
2019-06-30 -6.13
2019-03-31 -6.32
2018-12-31 -6.32
2018-09-30 -6.21
2018-06-30 -5.63
2018-03-31 -4.74
2017-12-31 -3.97
2017-09-30 -3.53
2017-06-30 -4.03
2017-03-31 -3.86

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cardax will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of CDXI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Cardax's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cardax's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cardax's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cardax has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CDXI Past Performance

  How has Cardax performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cardax's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cardax does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cardax's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cardax's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cardax's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cardax Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CDXI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.71 -5.09 4.09 0.32
2019-09-30 0.82 -4.60 4.34 0.31
2019-06-30 1.14 -4.09 4.34 0.25
2019-03-31 1.36 -4.11 4.50 0.25
2018-12-31 1.51 -4.02 4.53 0.27
2018-09-30 1.25 -3.87 4.28 0.24
2018-06-30 1.02 -3.30 3.66 0.15
2018-03-31 0.82 -2.58 2.97 0.04
2017-12-31 0.61 -1.99 2.21 0.10
2017-09-30 0.52 -1.59 1.70 0.16
2017-06-30 0.21 -1.71 1.57 0.25
2017-03-31 0.14 -1.56 1.26 0.40
2016-12-31 0.04 -1.78 1.47 0.35
2016-09-30 0.01 -3.20 1.87 0.40
2016-06-30 -3.46 2.20 0.33
2016-03-31 -3.82 2.61 0.27
2015-12-31 -4.26 2.93 0.49
2015-09-30 -4.25 3.79 0.59
2015-06-30 -5.39 4.57 0.94
2015-03-31 -6.83 5.69 1.20
2014-12-31 -16.99 15.68 1.16
2014-09-30 -16.70 15.12 1.19
2014-06-30 -16.17 14.38 1.16
2014-03-31 -15.05 13.27 1.02
2013-12-31 -4.36 2.63 0.94
2013-09-30 0.00 -3.51 1.91 0.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cardax has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Cardax has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cardax improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Cardax's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cardax has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CDXI Health

 How is Cardax's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cardax's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cardax's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Cardax's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cardax's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Cardax has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cardax Company Filings, last reported 3 months ago.

OTCPK:CDXI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -7.20 2.59 0.02
2019-09-30 -6.26 2.37 0.13
2019-06-30 -5.12 1.55 0.15
2019-03-31 -4.45 1.00 0.19
2018-12-31 -3.54 0.00 0.36
2018-09-30 -3.33 0.00 0.32
2018-06-30 -3.29 0.00 0.45
2018-03-31 -2.32 0.00 1.41
2017-12-31 -1.41 0.00 2.33
2017-09-30 -0.84 0.00 3.00
2017-06-30 -4.01 0.00 0.17
2017-03-31 -4.01 0.00 0.19
2016-12-31 -3.89 0.00 0.28
2016-09-30 -3.84 0.00 0.33
2016-06-30 -3.71 0.00 0.51
2016-03-31 -4.04 0.00 0.15
2015-12-31 -3.75 0.00 0.41
2015-09-30 -2.66 0.00 0.50
2015-06-30 -2.51 0.00 0.67
2015-03-31 -3.59 0.03 0.25
2014-12-31 -3.21 0.00 0.13
2014-09-30 -2.29 0.00 0.83
2014-06-30 -1.20 0.00 1.97
2014-03-31 -0.07 0.00 3.03
2013-12-31 -12.94 9.04 0.32
2013-09-30 -11.43 8.84 1.30
  • Cardax has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Cardax's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cardax has less than a year of cash runway based on current free cash flow.
  • Cardax has less than a year of cash runway if free cash flow continues to reduce at historical rates of -9.7% each year.
X
Financial health checks
We assess Cardax's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cardax has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CDXI Dividends

 What is Cardax's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cardax dividends.
If you bought $2,000 of Cardax shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cardax's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cardax's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CDXI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1933 Stocks 2.8%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cardax has not reported any payouts.
  • Unable to verify if Cardax's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cardax's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cardax has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cardax's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cardax afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cardax has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CDXI Management

 What is the CEO of Cardax's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Watumull
COMPENSATION $198,651
AGE 69
TENURE AS CEO 6.2 years
CEO Bio

Mr. David G. Watumull has been the Chief Executive Officer and President of Cardax, Inc. (also know as Koffee Korner Inc.) since February 7, 2014. Mr. Watumull served as the President and Chief Executive Officer of Hawaii Biotech, Inc. He is co-founder of Cardax Pharmaceuticals. He has more than twenty years experience as a biotech industry executive, analyst and investment banker. He served as an Executive Vice-President of Strategic Development and Corporate Finance at Mera Pharmaceuticals Inc. from July, 1998 to December, 2000. Mr. Watumull served as Consultant of Mera Pharmaceuticals Inc. (formerly, Aquasearch, Inc.) from September 1997 to 1998. He served as the Senior Vice-President of First Honolulu Securities, Inc. (“First Honolulu“), a Honolulu based broker-dealer and investment banker and as the Chief Investment Officer of First Honolulu's Asset Management Division, First Honolulu Securities Asset Management, from 1993 to 1997. At First Honolulu, Mr. Watumull served as Biotechnology Industry Analyst with clients that included the Wisconsin State Investment Board from 1993 to 1997. Mr. Watumull owned his own investment management firm specializing in biotechnology. He served as Money Manager and retail broker of Paine Webber in Honolulu from 1983 to 1992. He served as a Director of PBS Hawaii. Mr. Watumull has been a Director of Cardax, Inc. since February 7, 2014. Mr. Watumull served as a Director of Hawaii Biotech, Inc. Mr. Watumull is also incoming Chairman of the Hawaii Science and Technology Council, the industry's trade association in Hawaii. He was named one of Hawaii's Ten Who Made a Difference by the Honolulu Star-Bulletin for 1994. Mr. Watumull graduated from Punahou School and attended Claremont Men's College (now Claremont McKenna), majoring in mathematics and has lectured at the University of Hawaii business school.

CEO Compensation
  • David's compensation has increased whilst company is loss making.
  • David's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cardax management team in years:

6.5
Average Tenure
46
Average Age
  • The average tenure for the Cardax management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

David Watumull

TITLE
President
COMPENSATION
$199K
AGE
69
TENURE
6.2 yrs

David Watumull

TITLE
COO, Secretary & Assistant Treasurer
COMPENSATION
$156K
AGE
37
TENURE
6.9 yrs

Gilbert Rishton

TITLE
Chief Science Officer
COMPENSATION
$128K
TENURE
11.3 yrs

John Russell

TITLE
CFO & Treasurer
AGE
46
TENURE
6.2 yrs

Gilbert Shin

TITLE
Vice President of Retail Sales & Marketing
TENURE
2.3 yrs

Jon Ruckle

TITLE
Chief Medical Officer
TENURE
7.3 yrs
Board of Directors Tenure

Average tenure and age of the Cardax board of directors in years:

3.7
Average Tenure
62
Average Age
  • The tenure for the Cardax board of directors is about average.
Board of Directors

George Bickerstaff

TITLE
Independent Chairman
COMPENSATION
$75K
AGE
63
TENURE
3.7 yrs

David Watumull

TITLE
President
COMPENSATION
$199K
AGE
69
TENURE
6.2 yrs

Deepak Bhatt

TITLE
Chairman of Scientific Advisory Board
TENURE
13.3 yrs

Terence Kelly

TITLE
Independent Director
COMPENSATION
$75K
AGE
57
TENURE
5.8 yrs

Michele Galen

TITLE
Independent Director
COMPENSATION
$75K
AGE
62
TENURE
3.3 yrs

Elona Kogan

TITLE
Independent Director
COMPENSATION
$75K
AGE
50
TENURE
1.8 yrs

R. Mason

TITLE
Member of Scientific Advisory Board
TENURE
13.3 yrs

Mak Jawadekar

TITLE
Independent Director
COMPENSATION
$75K
AGE
68
TENURE
1.8 yrs

Paresh Soni

TITLE
Chief Clinical & Regulatory Strategist and Member of Scientific Advisory Board
AGE
59
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Cardax's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cardax has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CDXI News

Simply Wall St News

CDXI Company Info

Description

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate; and CDX-301, a zeaxanthin pharmaceutical candidate for pharmaceutical applications. The company has a joint development and supply agreement with BASF SE, as well as a collaboration agreement with Capsugel US, LLC for the development of astaxanthin products for the consumer health market. Cardax, Inc. is based in Honolulu, Hawaii.

Details
Name: Cardax, Inc.
CDXI
Exchange: OTCPK
Founded:
$4,553,838
758,973
Website: http://www.cardaxpharma.com
Address: Cardax, Inc.
2800 Woodlawn Drive,
Suite 129,
Honolulu,
Hawaii, 96822,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK CDXI New Common Stock Pink Sheets LLC US USD 10. Feb 2014
Number of employees
Current staff
Staff numbers
12
Cardax employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 04:38
End of day share price update: 2020/03/27 00:00
Last earnings filing: 2020/03/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.